Document:

Exhibit
      10.5

    Dawson
      James Securities

    

    March
      31,
      2008

    

    

    Lifesciences
      Opportunities Incorporated

    8447
      Wilshire Boulevard

    Suite
      102

    Beverly
      Hills, CA 90211

    Attn:
      James Morel 

    

    Re:
      Amended
      and Restated Selling Agreement (the “Agreement”)

    

    Dear
      Mr.
      Morel:

    

    This
      Agreement is intended to amend and restate in its entirety the Selling Agreement
      by and between Lifesciences Opportunities Incorporated, a Florida corporation
      (the “Seller”) and Dawson James Securities, Inc. (“Selling Agent”) dated
      February 27, 2008.

    

    The
      Seller proposes to offer and sell (the “Offering”), to selected investors, upon
      the terms set forth herein and in the Confidential Private Placement Memorandum
      dated March 31, 2008 (which collectively, together with the attachments and
      exhibits thereto, is referred to as the “Offering Document”), a copy of which
      has been delivered to you, up to 8,000 Units ($800,000) on an all-or-none basis,
      although the Company may accept subscriptions for up to an additional 2,000
      Units ($200,000), in its sole discretion (“Maximum Offering Amount”). The
      initial closing will not occur until a minimum of 8,000 Units has been sold.
      Each Unit consists of a convertible debenture in the principal amount of $1,000
      (the “Debentures”) and one thousand (1,000) shares (the “Additional Shares”) of
      the Company’s common stock, par value $.0001 (“Common Stock”). The Debentures
      and the Additional Shares being offered are sometimes referred to herein as
      the
“Offered Securities.” 

    

    Selling
      Agent agrees to offer and sell the Offered Securities on an exclusive basis
      during the period in which the Units are being offered (the “Offering Period”).
      Capitalized terms used and not otherwise defined herein shall have the
      respective meanings set forth in the Offering Document. It is intended that
      the
      offer, offer for sale and sale of the Offered Securities will be made only
      to
“accredited investors” (as such term is defined in Rule 501(a) of Regulation D
      of the Securities Act of 1933, as amended (the “1933 Act”) and will be exempt
      from the federal registration requirements of the 1933 Act, pursuant to
      Regulation D promulgated under Section 3(b) and/or Section 4(2),
      respectively, of the 1933 Act and will qualify for an exemption from
      registration, if necessary, under the applicable state securities laws and
      regulations.

    

    The
      Seller hereby confirms its agreement with Selling Agent as follows:

    

    1. Offer
      and Sale of Offered Securities by Selling Agent; Compensation;
      Closing.

    

    1.1 On
      the
      basis of Selling Agent’s representations, covenants and warranties, the Seller
      appoints Selling Agent the exclusive agent of the Seller for the period
      commencing on the date of the completion of the Offering Document and ending
      on
      the earlier of the date on which the Seller’s Board of Directors and the Selling
      Agent mutually agree to close the Offering or the Maximum Offering Amount is
      obtained and the subscriptions therefor have been accepted by Seller (“Offering
      Termination Date”), to use Selling Agent’s best efforts to offer and sell, on
      the terms and conditions set forth in this Agreement and in the Offering
      Document, subject only to Selling Agent’s right to engage participating
      broker-dealers pursuant to Section 2 hereof. The Selling Agent hereby
      accepts such appointment and agrees pursuant to the terms and conditions set
      forth herein and in the Offering Document to use its best efforts to offer
      and
      sell the Offered Securities as agent for the Seller during the period specified
      above, and to attempt to find suitable accredited purchasers for the Offered
      Securities acceptable to the Seller. 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    1.2 Prior
      to
      and subject to the closing, subscription proceeds from the sale of the Offered
      Securities will be deposited in an escrow account with an escrow agent to be
      mutually agreeable to Seller and the Selling Agent (the “Escrow Agent”). The
      Seller will be responsible for setting up the Escrow Account, pursuant to an
      escrow agreement among the Seller, the Selling Agent and the Escrow Agent,
      which
      escrow agreement will be approved by the Selling Agent. Subscribers will be
      instructed to make their checks payable to the Escrow Agent for the benefit
      of
      Lifesciences Opportunities Incorporated, or shall cause the wire transfer of
      immediately available funds in favor of the Escrow Agent for Lifesciences
      Opportunities Incorporated, in accordance with instructions provided by the
      Selling Agent. At the end of the Offering Period (as the same may be extended
      by
      the mutual agreement of the Selling Agent and the Seller), a closing (the
“Closing”) will occur as soon as possible after subscriptions have been accepted
      by the Seller and all other conditions precedent to closing have occurred to
      the
      sole satisfaction of the Selling Agent. 

    

    1.3 For
      purposes hereof, the Offered Securities shall not be deemed to have been sold
      unless (x) subscription agreements, completed and fully executed by subscribers
      who are accredited investors have been received covering the Offered Securities;
      (y) all checks, drafts and wire transfers submitted by such subscribers in
      payment of the purchase price of such Offered Securities have been received
      by
      the Escrow Agent and have cleared so that there are “good funds” in the Escrow
      Account at least equal to the aggregate purchase price of the Offered
      Securities; and (z) the minimum offering amount of $800,000 has been obtained
      and received by the Escrow Agent.

    

    1.4 As
      compensation for the Selling Agent’s services hereunder, the Seller shall pay to
      Selling Agent in cash a selling commission (“Commission”) upon the Closing, in
      an amount equal to ten percent (10%) of the aggregate offering price of the
      Offered Securities sold by the Selling Agent or its authorized agent at such
      Closing. At the Closing of the Offering, the Seller shall pay the Selling Agent
      its Commission relating to the sale of the Offered Securities that are subject
      of the Closing provided that the Seller or counsel for the Seller has received
      all documents, including but not limited to, an executed Subscription Agreement
      for each investor (“Subscription Documents”) previously furnished to Selling
      Agent which the Selling Agent is required to deliver to the Seller or counsel
      for the Seller prior to Closing. All or any portion of such Commission may
      be
      re-allowed to Participating Broker-Dealers (as hereinafter defined). No Offered
      Securities shall be considered to have been sold by Selling Agent or any
      Participating Broker-Dealer selected by Selling Agent unless the purchaser
      is
      acceptable to the Seller, and no compensation will be payable with respect
      to
      any agreement for the purchase of Offered Securities if the Subscription
      Agreement therefor is not actually accepted by the Seller. Anything in this
      Agreement to the contrary notwithstanding, the Seller shall not be required
      to
      pay a Commission to Selling Agent and Selling Agent shall not be entitled to
      a
      Commission, pursuant to this Section 1.4 or any other provision, if to do
      so would cause the Seller to violate federal or state securities laws,
      regulations or rules or any other law applicable to the Offering. 

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

    1.5 The
      Seller will pay all of its costs relating to the Offering contemplated hereby,
      including, without limitation, audit expenses, issuance costs and taxes, counsel
      fees for the preparation of the Offering Documents, filing fees and
      disbursements of counsel relating to the qualification of the Offered Securities
      under federal securities laws, and legal fees and expenses of counsel in
      connection with qualifying the Offered Securities under the state blue sky
      laws.
      To the extent required by law, the Seller shall qualify the Offered Securities
      for offer and sale in those jurisdictions designated by the Selling Agent and
      reasonably acceptable to the Seller. The Seller’s counsel shall be responsible
      for state blue sky securities laws compliance by the Seller.

    

    1.6 [Intentionally
      deleted].

    

    1.7 Once
      the
      Offered Securities are sold, or the Offering Period terminates, the agency
      between the Seller and the Selling Agent shall terminate. The Selling Agent,
      on
      the basis of the representations and warranties herein contained, but subject
      to
      the terms and conditions herein set forth, accepts such appointment as the
      limited agent of the Seller and agrees to use its best efforts to find
      purchasers for the Offered Securities.

    

    1.8 Upon
      the
      Closing of the sale of the Offered Securities offered by the Seller hereunder,
      the Seller will issue to the Selling Agent at a purchase price of $.001 per
      warrant, warrants to purchase shares of Common Stock equal to 10% of the
      Additional Shares contained in the Units sold by Selling Agent or Participating
      Broker-Dealers in the Offering (“Selling Agent’s Warrants”). The Selling Agent’s
      Warrants shall be exercisable at any time during the five (5) years from the
      date of Closing at an exercise price equal to $1.00 per share of Common Stock
      and shall have piggy-back registration rights. The Selling Agent’s Warrants
      shall be in the form and shall contain the provisions set forth in Exhibit
      A
      attached
      hereto. 

    

    1.9 The
      Closing(s) shall be held at the offices of the Selling Agent, 925 S. Federal
      Highway, 6th
      Floor,
      Boca Raton, FL 33432, or in an alternative location and at such time and date
      as
      Selling Agent and the Seller may mutually agree.

    

    1.10
       The
      holders of the Offered Securities will be provided with registration rights
      as
      set forth in the Offering Document with respect to the shares of Common Stock
      underlying the Debentures and the Additional Shares. The Additional Shares
      shall
      also be subject to the terms of the lock-up agreement as set forth in the
      Offering Document.

    

    2. Participating
      Broker-Dealers.
      The
      Seller hereby authorizes Selling Agent to engage other qualified broker-dealers
      (the “Participating Broker-Dealers”) to assist the Selling Agent in the
      placement of the Offered Securities; provided that during all times that each
      such Participating Broker-Dealer shall offer and sell the Offered Securities,
      each such Participating Broker-Dealer shall be registered as a broker-dealer
      under the Securities Exchange Act of 1934 (the “1934 Act”), shall be a member in
      good standing of the Financial Industry Regulatory Authority (“FINRA”), and
      shall be authorized to offer and sell the Offered Securities under the laws
      of
      the jurisdictions in which the Offered Securities will be offered and sold
      by
      such Participating Broker-Dealer. All Participating Broker-Dealers will be
      required to execute a Participating Broker-Dealer Agreement, the form of which
      is subject to the reasonable approval of the Seller, with Selling Agent
      containing substantially the same terms and conditions as this Agreement,
      including, without limitation, the representations and warranties contained
      in
      Section 3.2 below and provisions for indemnification of the Seller to the
      same extent as your indemnification provided in Section 7 below. Any
      commissions, fees, or expenses payable to such Participating Broker-Dealers
      will
      be paid by the Selling Agent and not by the Seller.

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    3. Representations,
      Warranties and Covenants.

    

    3.1 The
      Seller represents, warrants and covenants to Selling Agent that, except as
      set
      forth in Schedule 3.1 hereof or in the Offering Document:

    

    (a) The
      Seller and each subsidiary is a corporation duly formed and validly existing
      and
      in good standing under the laws of the jurisdiction of its incorporation as
      in
      effect on the date of this Agreement, with adequate power and authority to
      enter
      into and perform this Agreement and to own its property and to conduct its
      business as described in the Offering Document and in Seller’s
      reports required to be filed by it with the SEC pursuant to the 1933 Act, the
      1934 Act or otherwise (“SEC Reports”);
      and the
      Seller and each subsidiary is duly qualified as a foreign corporation to
      transact business and is in good standing in each jurisdiction in which it
      owns
      or leases substantial properties or in which the conduct of its business
      requires such qualification except for such jurisdictions in which the failure
      to qualify in the aggregate would not have material and adverse effect on the
      earnings, affairs or business prospects of the Seller or any such subsidiary
      (a
“Material Adverse Effect”) and in which jurisdictions such failure may be cured
      without such Material Adverse Effects; the execution and delivery of this
      Agreement by the Seller has been duly and validly authorized and will not result
      in a breach of its Articles of Incorporation or By-laws; and when executed
      and
      delivered by both parties hereto, this Agreement will be a valid and binding
      obligation of the Seller, assuming the due execution by the Selling Agent,
      enforceable in accordance with its terms (except to the extent that
      enforceability of the indemnification provisions may be limited under applicable
      securities laws and except as enforcement may be limited by bankruptcy,
      moratorium or other laws affecting creditors’ rights or general principles of
      equity); and the execution and delivery of this Agreement, the consummation
      of
      the transactions herein contemplated and compliance with the terms of this
      Agreement by the Seller do not and will not conflict with or result in a breach
      of any of the terms or provisions of, or constitute a default under, any
      agreement or any applicable law, rule, regulation, judgment, order or decree
      of
      any government, government instrumentality or court, domestic or foreign, having
      jurisdiction over the Seller, to which the Seller is a party or by which it
      is
      bound;

    

    (b) To
      the
      best of the its knowledge and belief, the Offering Document and the SEC Reports
      do not contain and will not contain, at any time between the date hereof and
      to
      and including the date of each Closing, any untrue statement of a material
      fact
      and does not omit nor during such period will omit to state a material fact
      required to be stated therein or necessary to make the statements therein,
      in
      light of the circumstances under which they were made, not misleading;

    

    (c) Except
      as
      is otherwise disclosed in the Offering Document or the SEC Reports, there is
      no
      litigation or governmental proceeding pending or, to the best of its knowledge,
      threatened against or involving the property or business of the Seller or any
      subsidiary of the Seller that would result in a Material Adverse
      Effect;

    

    (d) Except
      as
      is otherwise disclosed in the Offering Document or the SEC Reports, no material
      defaults exist in the due performance and observance of any material obligation,
      term, covenant or condition of any agreement or instrument to which the Seller
      or any subsidiary is a party or by which they are bound that would result in
      a
      Material Adverse Effect;

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

    (e) The
      offer, offer for sale, and sale of the Offered Securities have not been and
      will
      not be registered with the Securities and Exchange Commission (the “SEC”) except
      as contemplated in the Offering Document. The Company’s actions with respect to
      the offer, offer for sale and sale of the Offered Securities will be pursuant
      to
      the exemptions from the registration requirements of Section 5 of the 1933
      Act provided by Section 4(2) thereof and/or by Regulation D
      thereunder;

    

    (f) To
      the
      best of its knowledge and belief, assuming the offer, offer for sale and sale
      of
      the Offered Securities is made in compliance with the terms of the Offering
      Document, the applicable filings with the SEC and any applicable Blue Sky laws,
      and subject to the performance of the Selling Agent’s obligations hereunder, the
      Seller will have complied in all material respects with the 1933 Act and with
      all state securities laws and regulations applicable to it in connection with
      the offer, offer for sale, and sale of the Offered Securities. The Seller has
      not taken and will not take any action in conflict with the 1933 Act or
      applicable state or foreign securities or Blue Sky laws, or which would make
      the
      exemption, qualification or registration pursuant to applicable federal or
      state
      securities or Blue Sky laws unavailable with respect to the offer, offer for
      sale and sale of the Offered Securities. The Seller and its officers, directors
      or partners are not subject to any disqualification, including but not limited
      to any judgment, decree, order or decision issued by the SEC, any state or
      foreign securities regulatory authority, any court of competent jurisdiction
      or
      the United States Postal Service. In offering the Offered Securities, the Seller
      will comply with all applicable federal, state or foreign securities laws,
      including the rules covering exemptions from registration;

    

    (g) Subject
      to the performance of the Selling Agent’s obligations hereunder, the Offered
      Securities, upon the payment therefor and issuance thereof, will conform to
      all
      statements and descriptions in relation thereto contained in the Offering
      Document and will have the rights set forth in the Seller’s Articles of
      Incorporation;

    

    (h) To
      the
      best of the Seller’s knowledge, the Seller has neither been engaged in, nor been
      the subject of, any of the actions or proceedings specified in
      subsection (a) of Rule 262 promulgated under Section 3(b) of the
      1933 Act, or any substantially similar provisions under the securities laws
      of
      any state in which the Offered Securities are to be sold, such that no exemption
      from registration would be available for the offering of the Offered Securities
      by the Seller under applicable federal or state securities laws;

    

    (i) Since
      the
      respective dates as of which information is given in the SEC Reports, (i) there
      has been no material adverse change in the condition, business, property,
      capital commitments, working capital and liabilities or prospects of the Seller
      or any subsidiary, financial or otherwise; (ii) the property and business of
      the
      Seller materially conform to the descriptions thereof contained in the SEC
      Reports; (iii) there have been no material liabilities or obligations incurred
      or material transactions entered into by the Seller or any subsidiary other
      than
      those in the ordinary course of business; (iv) there have been no dividends
      or
      distributions of any kind declared, paid or made by the Seller on its capital
      stock; (v) there has not been any change in the capital stock, or any material
      increase in the current or long-term debt except as disclosed in the SEC
      Reports, or any issuance of options, warrants, convertible securities or other
      rights to purchase the capital stock of the Seller or any subsidiary; and (vi)
      there have been no transactions between the Seller, shareholders owning five
      percent (5%) or more of its issued and outstanding capital stock, the Seller’s
      officers and/or directors, nor have there been any corporate opportunities
      taken
      or assumed by controlling shareholders, officers or directors, that are not
      fully disclosed in the SEC Reports.

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

    (j) The
      Seller will notify the Selling Agent immediately and confirm the notice in
      writing (i) of the issuance by the SEC or by any state attorney general or
      securities administrator of any order enjoining the sale of the Offered
      Securities or suspending the effectiveness of any qualification of the Offered
      Securities for sale or (ii) of the initiation of any proceedings for that
      purpose. The Seller will make every reasonable effort to prevent the issuance
      of
      any such order and, if any such order shall at any time be issued, to obtain
      the
      lifting thereof at the earliest possible moment;

    

    (k) The
      audited and unaudited combined financial statements of the Seller (including
      the
      related notes) included in the SEC Reports present fairly the financial position
      of the Seller and its subsidiaries at the dates indicated; said financial
      statements have been prepared in conformity with United States generally
      accepted accounting principles applied on a consistent basis, except as
      expressly qualified therein, and are in conformity with Regulation S-X
      promulgated under the Act;

    

    (l) Except
      as
      set forth in the SEC Reports, the Seller does not have any subsidiaries and
      does
      not own any interest in any other corporation, partnership, joint venture or
      other entity;

    

    (m) As
      of the
      date of this Agreement, the Seller and its subsidiaries have not agreed, or
      agreed in principle, to any merger or acquisition, or combination with, of
      any
      other corporation, partnership, person, party, entity or trust or the sale
      of
      its business or assets to any other corporation, partnership, person, party,
      entity or trust;

    

    (n) The
      Seller and its subsidiaries have not, directly or indirectly, at any time during
      their existence (i) made any unlawful contribution to any candidate for
      political office, or failed to disclose fully any contribution in violation
      of
      law, or (ii) made any payment to any federal, state or foreign governmental
      officer or official, or other person charged with similar public or quasi-public
      duties, other than payments required or permitted by the laws of the United
      States or any jurisdiction thereof;

    

    (o) To
      the
      best of Seller’s knowledge, the Seller and its subsidiaries have filed all
      necessary federal, state, local, foreign and other tax returns required to
      be
      filed by them and have paid all taxes shown as due thereon; the Seller and
      its
      subsidiaries have not been notified, either orally or in writing, that any
      state, local, federal or foreign taxing authority is conducting or intends
      to
      conduct an audit of any tax return or report filed by the Seller and its
      subsidiaries or concerning their business or properties; and the Seller has
      no
      knowledge of any tax deficiency which has been asserted or threatened against
      the Seller and any subsidiary which would materially and adversely affect the
      business, properties, financial condition, results of operations, liabilities
      or
      working capital of the Seller;

    

    (p) The
      Seller and its subsidiaries make and keep accurate books and records and
      maintain internal accounting controls which provide reasonable assurance that
      (i) transactions are executed in accordance with management’s authorization,
      (ii) transactions are recorded as necessary to permit preparation of its
      financial statements and to maintain accountability for its assets, (iii) access
      to their assets is permitted only in accordance with management’s authorization,
      and (iv) the reported assets are compared with existing assets at reasonable
      intervals;

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

    

    (q) There
      are
      no pre-emptive rights applicable to any of the Seller’s outstanding securities,
      or granted by the Seller to any person or party;

    

    (r) The
      capitalization of the Seller is as described in the SEC Reports and the Seller
      has outstanding no more than 10,940 shares of its Series A Preferred Stock
      as of
      the date hereof; all presently outstanding shares of the Seller’s capital stock
      are duly and validly authorized and issued, fully paid and non-assessable and
      contain no preemptive rights; the Seller has not contracted for the issuance
      of
      any additional equity securities other than as set forth herein, or in the
      SEC
      Reports, or as contemplated or described in the Offering Document and no shares
      of any other classes of equity securities are issued and outstanding except
      as
      follows: 10,470,336 shares of Common Stock and warrants to purchase 1,146,492
      shares of Common Stock;

    

    (s) The
      Seller agrees that, for a period of twenty-four months (24) months from the
      date
      hereof, it shall not solicit any offer to buy from or offer to sell to any
      person introduced to the Seller by the Selling Agent in connection with the
      Offering, any securities of the Seller or provide the name of any such person
      to
      any other securities broker or dealer or selling agent. For
      purposes of this subsection, a person shall be considered to have been
“introduced to the Seller” by the Selling Agent only so long as Seller delivers
      an investment presentation to such person as part of the “road show” for the
      Offering as arranged by the Selling Agent, each of whose name(s) shall be
      thereafter listed and set forth on a schedule to this Agreement, which shall
      be
      updated from time to time. In
      the
      event that the Seller or any of its affiliates, directly or indirectly,
      solicits, offers to buy from or offers to sell to any such person any such
      securities, or provides the name of any such person to any other securities
      broker or dealer or selling agent, and such person purchases such securities
      or
      purchases securities of the Seller from any other securities broker or dealer
      or
      selling agent, the Seller shall pay to the Selling Agent an amount equal to
      ten
      percent (10.0%) of the aggregate purchase price of the securities so purchased
      by such person.

    

    (t) To
      the
      best of its knowledge and belief, the Seller is currently in compliance with
      (i)
      all applicable, material provisions of the Sarbanes-Oxley Act of 2002, and
      the
      rules and regulations promulgated thereunder, and (ii) all listing standards
      and
      rules promulgated by the FINRA applicable to Seller, except to the extent that
      non-compliance with such requirements in subsections (i) or (ii) would not
      result in a Material Adverse Effect.

    

    (u) All
      shares of Common Stock to be issued pursuant to this Offering (including shares
      of Common Stock underlying the Debentures) shall be delivered to the investors
      or the Selling Agent, as may be applicable, in the form of a physical
      certificate and not electronically, unless some other arrangement is mutually
      agreed to by the parties hereto.

    

    3.2 The
      Selling Agent represents and warrants to the Seller as follows:

    

    (a) The
      Selling Agent is, has been and will be at all times during the Offering Period,
      a Florida corporation duly organized and validly existing under the laws of
      the
      state of its incorporation, with all requisite power and authority to enter
      into
      and perform this Agreement; the execution and delivery of this Agreement by
      the
      Selling Agent has been duly and validly authorized; and when executed and
      delivered by the Seller, this Agreement will be a valid and binding obligation
      of the Selling Agent enforceable in accordance with its terms subject to:
      (i) due authorization, execution and delivery hereof by the Seller; (ii)
      the enforcement of remedies under applicable bankruptcy, insolvency and other
      laws affecting creditors’ rights generally and moratorium laws from time to time
      in effect; (iii) general equitable principles which may limit the right to
      obtain the remedy of specific performance; and (iv) the public policy limitation
      on indemnification under the federal securities laws;

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

    (b) The
      Selling Agent shall not offer or sell the Offered Securities in any state or
      states without the approval of the Seller and completion by the Seller of all,
      or any, Blue Sky filings for such states and shall not offer or sell the Offered
      Securities in any state or states in which it is not qualified or registered
      as
      a broker-dealer or authorized to engage in the brokerage business;
      and

    

    (c) The
      Selling Agent is (i) a broker-dealer registered with the SEC pursuant to the
      1934 Act, and no proceeding has been initiated to revoke such registration;
      (ii)
      a member in good standing of the FINRA; and (iii) a broker-dealer registered
      with the securities authorities of each jurisdiction in which it is required
      to
      be registered in connection with the offers or sales of the Offered Securities,
      and all such offers or sales will be made only by individuals licensed as
      required by all applicable federal and state securities laws. The Selling Agent
      agrees to maintain each of the foregoing memberships and registrations in good
      standing throughout the Offering Period.

    

    4. Sale
      and Delivery of Offered Securities.

    

    4.1 No
      sale
      of Offered Securities shall take place or be regarded as effective unless and
      until accepted by the Seller, such acceptance to occur at Closing, and the
      Seller reserves the right in its sole and absolute discretion to refuse to
      sell
      Offered Securities to any or all persons at any time. Selling Agent shall send
      to the Seller and to the Escrow Agent designated in Section 1.2, with copies
      to
      counsel for the Seller, all acceptable executed Subscription Documents, promptly
      upon receipt of the same, subject to any reasonable delay occasioned by further
      inquiry as to a prospective purchaser’s qualification or requests by the Seller
      or Selling Agent for further information from a prospective purchaser. The
      Seller shall notify Selling Agent as to whom to send the originals of such
      executed Subscription Documents and to whom to send copies. Selling Agent shall
      promptly send each such prospective purchaser’s payment for his Offered
      Securities to the Escrow Agent. Subject to review by counsel for the Seller,
      the
      Seller shall notify Selling Agent whether such prospective purchaser will be
      accepted by the Seller at Closing within ten (10) business days after receipt
      of
      the executed subscription documents for each prospective purchaser of Offered
      Securities, but in no event later than the earlier of (i) the date the parties
      have agreed to for Closing or (ii) the Offering Termination Date. For every
      prospective purchaser of Offered Securities whose subscription is rejected
      in
      its entirety, the Seller will promptly return all of such prospective
      purchaser’s executed Subscription Documents to Selling Agent for return to the
      prospective purchaser, and will notify the Escrow Agent to return the funds
      received to such prospective purchaser without interest and without
      deduction.

    

    5. Conditions
      to the Obligations of the Seller.

    

    The
      obligations of the Seller hereunder are subject to the accuracy of Selling
      Agent’s representations and warranties, to the observance and performance by
      Selling Agent of its obligations hereunder, and to the following further
      conditions (any of which may be waived in writing in whole or in part by the
      Seller):

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

    (a) Selling
      Agent shall not have taken or failed to take any action at any time at or prior
      to Closing, which, in the opinion of the Seller or counsel for Seller, conflicts
      or would conflict with, or otherwise make unavailable, the exemption from
      registration requirements for the offer and sale of the Offered Securities
      under
      applicable securities laws and regulations.

    

    (b) If
      any of
      the conditions specified in this Section 5 shall not have been fulfilled
      when and as required by this Agreement to be fulfilled, all the obligations
      of
      the Seller under this Agreement may be terminated in writing at any time at
      or
      prior to Closing, and any such termination shall be without liability to the
      parties, and further provided that the obligations under Section 7 and
      Section 9.1 shall nevertheless survive and continue
      thereafter.

    

    6. Conditions
      of the Obligations of the Selling Agent.

    

    The
      obligations of the Selling Agent to act as agent hereunder, to find purchasers
      for the Offered Securities, and to attend and to deliver documents at Closing
      shall be subject to the following conditions:

    

    (a) Between
      the date hereof and Closing, the Seller and its subsidiaries shall not have
      sustained any loss on account of fire, explosion, flood, accident, calamity
      or
      other cause, of such character as results in a Material Adverse Effect on the
      Seller and its subsidiaries, whether or not such loss is covered by
      insurance.

    

    (b) Between
      the date hereof and Closing, there shall be no material litigation instituted
      or
      threatened against the Seller or any subsidiary (other than as set forth in
      the
      Offering Document or as disclosed to the Selling Agent) and there shall be
      no
      material proceeding instituted or threatened before or by any federal or state
      commission, regulatory body or administrative agency or other governmental
      body,
      domestic or foreign, wherein an unfavorable ruling, decision or finding would
      materially adversely affect the business, franchises, licenses, permits,
      operations or financial condition or income of the Seller.

    

    (c) Except
      as
      contemplated herein or as set forth in the Offering Document or in the SEC
      Reports, during the period subsequent to the date hereof, and prior to Closing,
      the Seller and each subsidiary: (i) shall have conducted its business in the
      usual and ordinary manner as the same was being conducted on the date hereof,
      and (ii) except in the ordinary course of its business or as disclosed to the
      Selling Agent, the Seller and each subsidiary shall not have incurred any
      liabilities or obligations (direct or contingent), or disposed of any assets,
      or
      entered into any material transaction or suffered or experienced any
      substantially adverse change in its condition, financial or otherwise, or in
      its
      working capital position. At Closing, the capitalization of the Seller shall
      be
      substantially the same as set forth in the Offering Document.

    

    (d) The
      authorization for the issuance and delivery of the Offered Securities and the
      Offering Document and related materials, and for the execution and delivery
      of
      this Agreement, and all other legal matters incident thereto, shall be
      reasonably satisfactory in all respects to counsel for Selling Agent.

    

    (e) The
      representations and warranties of the Seller made in this Agreement or in any
      document or certificate delivered to the Selling Agent pursuant hereto shall
      be
      true and correct on and as of the date of this Agreement or such document or
      certificate with the same force and effect as though such representations and
      warranties have been made on and as of the date of this Agreement or such
      document or certificate.

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

    (f) The
      Seller shall have performed and complied in all material respects with all
      covenants, terms and agreements to be performed and complied with by the Seller
      as contained in this Agreement on or before the Closing.

    

    (g) The
      Seller shall have provided such certificates as the Selling Agent shall
      reasonably request.

    

    

    7. Indemnification.

    

    7.1 The
      Seller agrees to indemnify and hold harmless Selling Agent and each person,
      if
      any, who controls Selling Agent within the meaning of the 1933 Act or the 1934
      Act (together, the “Acts”), the Selling Agent’s affiliated entities, partners,
      employees, legal counsel and agents (the “SA Indemnified Parties”) against any
      losses, claims, damages, obligations, penalties, judgments, awards, liabilities,
      costs, expenses and disbursements (and any and all actions, suits, proceedings
      and investigations in respect thereof and any and all legal and other costs,
      expenses and disbursements in giving testimony or furnishing documents in
      response to a subpoena or otherwise), joint or several, to which Selling Agent
      or such person may be subject, under the Acts or otherwise, including, without
      limitation, the costs, expenses and disbursements, as and when incurred, of
      investigating, preparing or defending any such action, suit, proceeding or
      investigation (whether or not in connection with litigation in which the Selling
      Agent is a party), directly or indirectly, caused by, relating to, based upon,
      arising out of, or in connection with (i) the violation or breach of any
      representation, warranty or covenant or agreement of the Seller set forth in
      this Agreement or in any instrument, document, agreement or certificate
      delivered by the Seller in connection herewith; (ii) any untrue statement or
      omission or any alleged untrue statement or omission in the Offering Document
      or
      selling material, excluding information contained in or omitted from the
      Offering Document or selling material in reliance upon, and in conformity with,
      information furnished to the Seller by Selling Agent or any Participating
      Broker-Dealer specifically for use in preparation of the Offering Document
      or
      selling material, as the case may be; (iii) any information provided by or
      on
      behalf of Seller in order to qualify or exempt the Offered Securities for sale
      in any jurisdiction; or (iv) the failure of the Seller to comply with the
      provisions of the Acts and the regulations thereunder, including
      Regulation D; and will reimburse the SA Indemnified Parties for any legal
      or other expenses reasonably incurred by the SA Indemnified Parties in
      connection with investigation of or defending against any such loss, claim,
      expense, damage, liability, (or actions in respect thereof); provided, however,
      that the Seller shall not be required to indemnify the SA Indemnified Parties
      for any payment made to any claimant in settlement of any suit or claim unless
      such payment is agreed to by the Seller (which agreement shall not be
      unreasonably withheld) or by a court having jurisdiction of the controversy.
      This indemnity agreement shall remain in full force and effect notwithstanding
      any investigation made by Selling Agent or on Selling Agent’s behalf, shall
      survive consummation of the sale of the Offered Securities hereunder and shall
      be in addition to any liability which the Seller may otherwise have.

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

    7.2 Selling
      Agent agrees to indemnify and hold harmless the Seller and each person, if
      any,
      who controls the Seller within the meaning of the Acts, Seller’s affiliated
      entities, partners, employees, legal counsel and agents (the “Seller Indemnified
      Parties”) against any losses, claims, damages, obligations, penalties,
      judgments, awards, liabilities, costs, expenses and disbursements (and any
      and
      all actions, suits, proceedings and investigations in respect thereof and any
      and all legal and other costs, expenses and disbursements in giving testimony
      or
      furnishing documents in response to a subpoena or otherwise), joint or several
      (including,
      without limitation, the costs, expenses and disbursements, as and when incurred,
      of investigating, preparing or defending any such action, suit, proceeding
      or
      investigation (whether or not in connection with litigation in which the Seller
      is a party)), to
      which
      the Seller or any such person may be subject, under the Acts or otherwise,
      insofar as such losses, claims, expenses, damages or liabilities (or actions
      in
      respect thereof) which (i) arise out of or are based upon any untrue statement
      or omission or any alleged untrue statement or omission in the Offering Document
      contained in or omitted from the Offering Document in reliance upon, and in
      conformity with, information furnished to the Seller by Selling Agent or any
      Participating Broker-Dealer or either of them specifically for use in
      preparation of the Offering Document or selling material, as the case may be
      or
      (ii)
      are directly or indirectly, caused by, relating to, based upon, arising out
      of,
      or in connection with the violation or breach of any representation, warranty
      or
      covenant or agreement of the Selling Agent set forth in this Agreement or in
      any
      instrument, document, agreement or certificate delivered by the Selling Agent
      in
      connection herewith);
      and
      will reimburse the Seller Indemnified Parties for any legal or other expenses
      reasonably incurred by them in connection with investigating or defending
      against any such loss, claim, expense, damage, liability, (or actions in respect
      thereof); provided, however, that Selling Agent shall not be required to
      indemnify the Seller Indemnified Parties for any payment made to any claimant
      in
      settlement of any suit or claim unless such payment is approved by a court
      having jurisdiction over the controversy or Selling Agent agrees to such
      settlement (which agreement shall not be unreasonably withheld); and provided
      further that Selling Agent shall not be liable under this Section 7.2 for
      any losses, claims, expenses, damages or liabilities arising out of any act
      or
      failure to act on the part of any other person except Selling Agent, its
      partners, employees and agents (including registered representatives) or any
      Participating Broker-Dealer. This indemnity agreement shall remain in full
      force
      and effect notwithstanding any investigation made by or on behalf of the Seller
      and shall survive consummation of the sale of the Offered Securities hereunder
      and the termination of this Agreement, and shall be in addition to any liability
      which Selling Agent may otherwise have. Notwithstanding the foregoing, in no
      event shall the amount that the Selling Agent is required to indemnify the
      Seller Indemnified Parties, exceed in the aggregate the compensation received
      by
      the Selling Agent hereunder, except in the case of fraud on the part of the
      Selling Agent.

    

    7.3 The
      indemnified party shall notify the indemnifying party in writing promptly after
      the summons or other first legal process giving information of the nature of
      any
      and all claims which have been served upon the indemnified party. In case any
      action is brought against any indemnified party upon any such claim, the
      indemnifying party shall be entitled to participate at its own expense in the
      defense, or if it so elects, in accordance with arrangements satisfactory to
      any
      other indemnifying party or parties similarly notified, to assume the defense
      thereof, with counsel who shall be satisfactory to such indemnified party and
      other indemnified parties who are defendants in such action; and after notice
      from the indemnifying party to such indemnified party of its election so to
      assume the defense thereof and the retaining of such counsel by the indemnifying
      party, the indemnifying party shall not be liable to such indemnified party
      under this Section 7 for any legal or other expenses subsequently incurred
      by such indemnified party in connection with the defense thereof, other than
      the
      reasonable costs of investigation, unless the indemnified party shall have
      reasonably concluded that there are or may be defenses available to it which
      are
      different from or in addition to those available to the indemnifying party
      (in
      which case the indemnifying party shall not have the right to direct the defense
      of such action on behalf of the indemnified party), in any of which
      circumstances such expenses shall be borne by the indemnifying party.

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

      

    8. Termination
      of Agreement.

    

    8.1 This
      Agreement shall terminate:

    

    (a) If
      at any
      time after commencement of the Offering, any material condition of Seller’s
      obligations hereunder shall not have been met or shall cease to be met and
      Selling Agent shall have given to the Seller notice of Selling Agent’s desire to
      terminate this Agreement on account of the nonfulfillment of such condition;
      or

    

    (b) At
      such
      time as the Offering Termination Date has been reached.

    

    Notwithstanding
      the termination of this Agreement in accordance with the foregoing provisions
      of
      this Section 8, the respective indemnities, covenants, agreements,
      representations, warranties and other statements of the Seller and Selling
      Agent
      set forth in or made pursuant to this Agreement will survive the Offering
      Termination date for a period of two (2) years.

    

    8.2 If
      this
      Agreement is terminated pursuant to Section 8.1(a) above, the Selling Agent
      shall have no liability to the Seller, and if this Agreement is terminated
      pursuant to Section 8.1(b) above, the Seller shall have no liability to the
      Selling Agent.

    

    9. Miscellaneous.

    

    9.1 Except
      as
      otherwise specifically provided in this Agreement or as may be otherwise agreed
      between the parties hereto, Selling Agent, on the one hand, and the Seller,
      on
      the other, shall each pay their respective expenses incident to this Agreement
      and the transactions contemplated hereby (including, without limitation, the
      fees and disbursements of their respective counsel), and no party to the
      Agreement shall have any liability for such expenses incurred by any other
      party.

    

    9.2 It
      is
      understood and agreed that Selling Agent’s relationship to the Seller is that of
      an independent contractor and that nothing herein shall be construed to create
      a
      relationship of partners, affiliates, joint venturers or employer and employee
      between Selling Agent or either of them and the Seller.

    

    9.3 No
      rights
      or interests arising hereunder may be assigned except with the prior written
      consent of both the Seller and the Selling Agent. Subject to this limitation,
      this Agreement shall inure to the benefit and be binding upon Selling Agent
      and
      the Seller and their respective successors and assigns. This Agreement is
      intended to be and is for the sole and exclusive benefit of the parties hereto,
      and their respective successors and assigns and for the benefit of no other
      person. Except as provided in this Agreement, nothing expressed or mentioned
      in
      this Agreement is intended or shall be construed to give any person, other
      than
      the parties to it and their respective successors and assigns, any legal or
      equitable right, remedy or claim under or with respect to this Agreement or
      any
      of its provisions. No purchaser of Offered Securities shall be construed as
      a
      successor or assign merely by reason of such purchase. 

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

      

    

     

    9.4 If
      any
      portion of this Agreement shall be held invalid or inoperative, then so far
      as
      is reasonable and possible:

    

    (a) the
      remainder of this Agreement shall be considered valid and operative;
      and

    

    (b) to
      the
      extent possible under applicable law, effect shall be given to the intent
      manifest by the portion held invalid or inoperative.

    

    9.5 This
      Agreement may be executed in a number of identical counterparts and by
      facsimile, each of which shall be deemed to be an original, but all of which
      constitute, collectively, one and the same Agreement; but, in making proof
      of
      this Agreement, it shall not be necessary to produce or account for more than
      one counterpart.

    

    9.6 This
      Agreement may not be modified or amended except by written agreement executed
      by
      each of the parties to this Agreement.

    

    9.7 Whenever
      the context so requires, the masculine shall include the feminine and neuter,
      and the singular shall include the plural, and conversely. The words “shall” and
“will” and “agrees” are mandatory, “may” is permissive.

    

    9.8 The
      parties to this Agreement covenant and agree that they will execute any other
      and further instruments and documents which reasonably are or may become
      necessary or convenient to effectuate and carry out this Agreement.

    

    9.9 This
      Agreement (and the other documents and agreements referenced herein) contains
      the entire understanding between the parties and supersedes prior understandings
      or written or oral agreements between the parties with respect to the subject
      matter of this Agreement.

    

    9.10 This
      Agreement shall be construed and governed by the laws of the State of Florida.
      Each party hereby consents to any and all actions or controversies arising
      from
      this agreement shall be have venue in the exclusive jurisdiction of the state
      and federal courts located in Palm Beach County, Florida. Any terms and
      conditions of this Agreement which are inconsistent with the terms and
      conditions of the Offering Document, shall be modified to conform to the terms
      and conditions set forth in the Offering Document.

    

    9.11 All
      notices or communications, except as otherwise specifically provided, shall
      be
      in writing, and, if sent to any party, shall be mailed, delivered or telegraphed
      and confirmed to that party at the address set forth below:

    

    

    
      	If to the Seller:	 	
              Lifesciences
                Opportunities Incorporated

              8500
                Wilshire Boulevard, Suite 105

              Beverly
                Hills, CA 90211

              Attention:
                Chief Executive Officer

            
	 	 	 
	With a copy
              contemporaneously	 	
              by
                like means:      

              Blank
                Rome LLP

              Bruce
                Rosetto, Esq.

              1200
                N. Federal Highway, Suite 417

              Boca
                Raton, FL 33432

              Facsimile:
                561-417-8186

            

    

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    

    
      	If to Selling Agent, to:	 	
              
                Dawson
                  James Securities, Inc.

                925
                  S. Federal Highway

                6th
                  Floor

                Boca
                  Raton, FL 33432

                Attention:
                  David Weinstein

              

            
	 

    

     

    9.12 All
      of
      the terms of this Agreement, including all representations, warranties,
      covenants and agreements of Selling Agent and the Seller, shall survive
      completion of the Offering for three years.

    

    9.13 Section
      titles or captions contained in this Agreement are inserted only as a matter
      of
      convenience and for reference. Those titles in no way define, limit, extend
      or
      describe the scope of this Agreement, or the intent of any provision of this
      Agreement.

    

    10.
      Right
      of First Refusal.
      The
      Seller will grant to the Selling Agent a right of first refusal for a period
      of
      twenty-four (24) months from the Closing Date of the Offered Securities being
      offered in this transaction to be engaged as placement agent for any public
      or
      private sale of securities of the Seller to be made by the Seller or any of
      its
      affiliates or subsidiaries.

    

    

    

    [Signature
      Page Follows]

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

    

    If
      the
      foregoing correctly sets forth the understanding between us, please indicate
      acceptance by signing in the space provided below for that purpose and return
      to
      us a counterpart hereof so signed, whereupon this letter and Selling Agent’s
      acceptance shall constitute a binding agreement between us.

    

    The
      foregoing Amended and Restated Selling Agreement for Lifesciences Opportunities
      Incorporated is hereby accepted and agreed to as of the date first above
      written.

     

    
      	
              Dawson
                James Securities, Inc.

              As
                Selling Agent

            	 	 	Lifesciences Opportunities
              Incorporated
	 	 	 	 
	
              By:
                /s/
                Robert D. Keyser, Jr.

            	 	 	By:
              /s/ James
              Morel 
	
              
                
Name:
                Robert D. Keyser, Jr.

              Its:
                CEO

            	 	 	
              
                
James
                Morel, CEO

            

    

     

     

    
      
        
        

      

      
        15Exhibit
      4.6

    

    THIS
      WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN ACQUIRED
      FOR
      INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
      AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. THIS WARRANT AND SUCH
      SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE PLEDGED, TRANSFERRED OR
      HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR DELIVERY OF AN OPINION
      OF
      COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
      OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE
      ACT
      OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER THE ACT.

     

    MANHATTAN
      PHARMACEUTICALS, INC.

    

    Warrant
      for the Purchase of Shares of

    Common
      Stock

    

    Issuance
      Date: April 30, 2008

    
      
        	
                No.
                  2008-1

              	
                7,142,857
                  Shares    

              

      

       

    

    FOR
      VALUE
      RECEIVED, MANHATTAN PHARMACEUTICALS, INC., a Delaware corporation (the
“Company”),
      hereby certifies that Nordic Biotech Venture Fund II K/S, its designee or its
      permitted assigns is entitled to purchase from the Company, at any time or
      from
      time to time commencing on April 30, 2008 and prior to 5:00 P.M., New York
      City
      time, on April 30, 2013 (the “Exercise
      Period”),
      7,142,857 fully paid and non-assessable shares of common stock, $0.001 par
      value
      per share, of the Company for a purchase price per share of $0.14. Hereinafter,
      (i) said common stock, $0.001 par value per share, of the Company, is referred
      to as the “Common
      Stock”;
      (ii)
      the shares of the Common Stock (subject to adjustment as set forth herein)
      purchasable hereunder or under any other Warrant (as hereinafter defined) are
      referred to as the “Warrant
      Shares”;
      (iii)
      the aggregate purchase price payable for the Warrant Shares purchasable
      hereunder is referred to as the “Aggregate
      Warrant Price”;
      (iv)
      the price payable (initially $0.14 per share subject to adjustment as set forth
      herein) for each of the Warrant Shares hereunder is referred to as the
“Per
      Share Warrant Price”;
      (v)
      this Warrant and all warrants hereafter issued in exchange or substitution
      for,
      or upon assignment or partial assignment of, this Warrant are referred to as
      the
“Warrants”;
      (vi)
      the registered holder of this Warrant is referred to as the “Holder”
and
      the
      holder of this Warrant and all other Warrants and Warrant Shares are referred
      to
      as the “Holders”
and
      Holders of at least two-thirds of the Warrant Shares then issuable upon exercise
      of then outstanding Warrants are referred to as the “Majority
      of the Holders”
and
      (vii) the then Current Market Price per share of the Common Stock (the
“Current
      Market Price”)
      shall
      be deemed to be the last reported sale price of the Common Stock on the Trading
      Day (as defined below) immediately prior to such date or, in case no such
      reported sales take place on such day, the average of the last reported bid
      and
      asked prices of the Common Stock on such day, in either case on the principal
      national securities exchange on which the Common Stock is admitted to trading
      or
      listed, or if not listed or admitted to trading on any such exchange, the per
      share sale price for the Common Stock in the over-the-counter market as reported
      by the OTC Bulletin Board or another over-the-counter market, or if not so
      available, the fair market value of the Common Stock as determined in good
      faith
      by the Company’s Board of Directors. A “Trading
      Day”
shall
      mean any day on which such principal exchange or market is open for trading,
      or
      if there is no such exchange or market, then any day except Saturdays, Sundays
      or federal holidays. The Aggregate Warrant Price is not subject to
      adjustment.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    1.
       Exercise
      of Warrant.
      

    

    (a)
      Exercise
      for Cash.
      This
      Warrant may be exercised in whole at any time, or in part from time to time,
      by
      the Holder during the Exercise Period by the surrender of this Warrant (with
      the
      subscription form at the end hereof duly executed) at the address set forth
      in
      subsection 9(a) hereof, together with proper payment of the Aggregate Warrant
      Price, or the proportionate part thereof if this Warrant is exercised in part,
      with payment for the Warrant Shares made by certified or official bank check
      payable to the order of, or wire transfer of immediately available funds to,
      the
      Company; or

     

    (b)
      Cashless
      Exercise. 

    

    (i)
      At
      any time during the Exercise Period the Holder may, at its option, elect to
      exercise this Warrant, in whole or in part, on a cashless basis, by surrendering
      this Warrant, with the form of subscription appended hereto duly executed by
      or
      on behalf of the Holder, at the principal office of the Company, or at such
      other office or agency as the Company may designate, by canceling a portion
      of
      this Warrant in payment of the Aggregate Warrant Price (or proportionate payment
      thereof in this Warrant is exercise in part) payable in respect of the number
      of
      Warrant Shares purchased upon such exercise. In the event of an exercise
      pursuant to this subsection 1(b), the number of Warrant Shares issued to the
      Holder shall be determined according to the following formula: 

     

    
      	
               

            	
              X
                =
                

            	
               Y(A-B)

            
	
               

            	
               

            	
              A

            
	
              Where:
                

            	
              X
                =
                

            	
              the
                number of Warrant Shares that shall be issued to the Holder;
                

            
	
               

            	
               

            	
               

            
	
               

            	
              Y
                =

            	
              the
                number of Warrant Shares for which this Warrant is being exercised
                (which
                shall include both the number of Warrant Shares issued to the Registered
                Holder and the number of Warrant Shares subject to the portion of
                the
                Warrant being cancelled in payment of the Purchase Price);
                

            
	
               

            	
               

            	
               

            
	
               

            	
              A
                =

            	
              the
                Fair Market Value (as defined below) of one share of Common Stock;
                and

            
	
               

            	
               

            	
               

            
	
               

            	
              B
                =

            	
              the
                Per Share Warrant Price then in
                effect.

            

    

     

       
      (ii)
      The
“Fair Market Value” per share of Common Stock shall be determined as
      follows:

     

    (1)
      If
      the Common Stock is listed on a national securities exchange, including the
      Nasdaq Global Market or the Nasdaq Capital Market, or another nationally
      recognized trading system as of the date of exercise, the Fair Market Value
      per
      share of Common Stock shall be deemed to be the average of the high and low
      reported sale prices per share of Common Stock thereon on the trading day
      immediately preceding the date of exercise (provided that if no such price
      is
      reported on such day, the Fair Market Value per share of Common Stock shall
      be
      determined pursuant to clause (2) below).

    

    (2)
      If
      the Common Stock is not listed on a national securities exchange, including
      the
      Nasdaq Global Market or the Nasdaq Capital Market, or another nationally
      recognized trading system as of the date of exercise, the Fair Market Value
      per
      share of Common Stock shall be deemed to be the amount most recently determined
      by the Board of Directors of the Company (the “Board”)
      to
      represent the fair market value per share of the Common Stock (including without
      limitation a determination for purposes of granting Common Stock options or
      issuing Common Stock under any plan, agreement or arrangement with employees
      of
      the Company); and, upon request of the Holder, the Board (or a representative
      thereof) shall, as promptly as reasonably practicable but in any event not
      later
      than 10 days after such request, notify the Holder of the Fair Market Value
      per
      share of Common Stock and furnish the Holder with reasonable documentation
      of
      the Board’s determination of such Fair Market Value. Notwithstanding the
      foregoing, if the Board has not made such a determination within the three-month
      period prior to the date of exercise, then (A) the Board shall make, and shall
      provide or cause to be provided to the Holder notice of, a determination of
      the
      Fair Market Value per share of the Common Stock within 15 days of a request
      by
      the Holder that it do so, and (B) the exercise of this Warrant pursuant to
      this
      subsection 1(b) shall be delayed until such determination is made and notice
      thereof is provided to the Holder.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    (c)
      If
      this Warrant is exercised in part, this Warrant must be exercised for a number
      of whole shares of the Common Stock and the Holder is entitled to receive a
      new
      Warrant covering the Warrant Shares that have not been exercised and setting
      forth the proportionate part of the Aggregate Warrant Price applicable to such
      Warrant Shares. Upon surrender of this Warrant in connection with the exercise
      of this Warrant pursuant to the terms hereof, the Company will (i) within three
      Trading Days of such exercise, issue a certificate or certificates in the name
      of the Holder for the largest number of whole shares of the Common Stock to
      which the Holder shall be entitled upon such exercise and, if this Warrant
      is
      exercised in whole, in lieu of any fractional share of the Common Stock to
      which
      the Holder shall be entitled, pay to the Holder cash in an amount equal to
      the
      Fair Market Value of such fractional share (as determined in accordance with
      subsection 1(b)), and (ii) deliver the other securities and properties
      receivable upon the exercise of this Warrant, or the proportionate part thereof,
      if this Warrant is exercised in part, pursuant to the provisions of this
      Warrant. If such certificates do not require a legend in accordance with this
      Agreement, the certificates
      representing the Warrant Shares exercised shall be transmitted by the transfer
      agent of the Company to the Holder by crediting the account of the Holder’s
      prime broker with the Depository Trust Company System.

    

    2. Reservation
      of Warrant Shares; Listing.
      The
      Company agrees that, prior to the expiration of this Warrant, the Company shall
      at all times (a) have authorized and in reserve, and shall keep available,
      solely for issuance and delivery upon the exercise of this Warrant, the shares
      of the Common Stock and other securities and properties as from time to time
      shall be receivable upon the exercise of this Warrant, free and clear of all
      restrictions on sale or transfer, other than under Federal or state securities
      laws, and free and clear of all preemptive rights and rights of first refusal
      and (b) as long as the Common Stock is listed on any national securities
      exchange, use its reasonable best efforts to keep the Warrant Shares authorized
      for listing on such exchange upon notice of issuance.

    

    3. Certain
      Adjustments.
      

     

    (a)
      In
      case the Company shall hereafter (i) pay a dividend or make a distribution
      on
      its Common Stock in shares of Common Stock, (ii) subdivide its outstanding
      shares of Common Stock into a greater number of shares, (iii) combine or
      reverse-split its outstanding shares of Common Stock into a smaller number
      of
      shares or (iv) issue by reclassification of its Common Stock any shares of
      capital stock of the Company, then the Per Share Warrant Price and the number
      of
      Warrant Shares shall forthwith be proportionately decreased and increased,
      respectively, in the case of a subdivision, distribution or stock dividend,
      or
      proportionately increased and decreased, respectively, in the case of a
      combination or reverse stock split. The Aggregate Warrant Price payable for
      the
      then total number of Warrant Shares available for exercise under this Warrant
      shall remain the same. Adjustments made pursuant to this subsection 3(a) shall
      become effective on the record date in the case of a dividend or distribution,
      and shall become effective immediately after the effective date in the case
      of a
      subdivision, combination or reclassification. If such dividend, distribution,
      subdivision or combination is not consummated in full, the Per Share Warrant
      Price and Warrant Shares shall be readjusted accordingly.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (b)
      In
      case of any capital reorganization or reclassification, or any consolidation
      or
      merger to which the Company is a party other than a merger or consolidation
      in
      which the Company is the continuing corporation, or in case of any sale or
      conveyance to another entity of all or substantially all of the assets of the
      Company, or in the case of any statutory exchange of securities with another
      corporation (including any exchange effected in connection with a merger of
      a
      third corporation into the Company but excluding any exchange of securities
      or
      merger with another corporation in which the Company is a continuing corporation
      and that does not result in any reclassification of or similar change in the
      Common Stock), the Holder of this Warrant shall have the right thereafter to
      receive on the exercise of this Warrant the kind and amount of securities,
      cash
      or other property which the Holder would have owned or have been entitled to
      receive immediately after such reorganization, reclassification, consolidation,
      merger, statutory exchange, sale or conveyance had this Warrant been exercised
      immediately prior to the effective date of such reorganization,
      reclassification, consolidation, merger, statutory exchange, sale or conveyance
      and in any such case, if necessary, appropriate adjustment shall be made in
      the
      application of the provisions set forth in this Section 3 with respect to the
      rights and interests thereafter of the Holder of this Warrant to the end that
      the provisions set forth in this Section 3 shall thereafter correspondingly
      be
      made applicable, as nearly as may reasonably be, in relation to any shares
      of
      stock or other securities or property thereafter deliverable on the exercise
      of
      this Warrant. The above provisions of this subsection 3(b) shall similarly
      apply
      to successive reorganizations, reclassifications, consolidations, mergers,
      statutory exchanges, sales or conveyances. The Company shall require the issuer
      of any shares of stock or other securities or property thereafter deliverable
      on
      the exercise of this Warrant to be responsible for all of the agreements and
      obligations of the Company hereunder. Notice of any such reorganization,
      reclassification, consolidation, merger, statutory exchange, sale or conveyance
      and of said provisions so proposed to be made, shall be mailed to the Holders
      of
      the Warrants not less than twenty (20) days prior to such event. A sale of
      all
      or substantially all of the assets of the Company for a consideration consisting
      primarily of securities shall be deemed a consolidation or merger for the
      foregoing purposes.

    

    (c)
      If
      the Company at any time while this Warrant is outstanding, shall sell or grant
      any option to purchase, or sell or grant any right to reprice its securities,
      or
      otherwise dispose of or issue (or announce any offer, sale, grant or any option
      to purchase or other disposition) any Common Stock or Common Stock Equivalents
      (as defined below) entitling any Person to acquire shares of Common Stock,
      at an
      effective price per share less than the then Per Share Warrant Price (such
      lower
      price, the “Base Share Price” and such issuances collectively, a “Dilutive
      Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so
      issued shall at any time, whether by operation of purchase price adjustments,
      reset provisions, floating conversion, exercise or exchange prices or otherwise,
      or due to warrants, options or rights per share which are issued in connection
      with such issuance, be entitled to receive shares of Common Stock at an
      effective price per share which is less than the Per Share Warrant Price, such
      issuance shall be deemed to have occurred for less than the Per Share Warrant
      Price on such date of the Dilutive Issuance), then the Per Share Warrant Price
      shall be reduced and only reduced to equal the Base Share Price and the number
      of Warrant Shares issuable hereunder shall be increased such that the aggregate
      Per Share Warrant Price payable hereunder, after taking into account the
      decrease in the Per Share Warrant Price, shall be equal to the aggregate Per
      Share Warrant Price prior to such adjustment. If shares of Common Stock or
      Common Stock Equivalents are issued or sold together with other stock or
      securities or other assets of the Company for a consideration which covers
      both,
      the effective price per share shall be computed with regard to the portion
      of
      the consideration so received that may be reasonably determined in good faith
      by
      the Board of Directors, to be allocable to such Common Stock or Common Stock
      Equivalents. Such
      adjustment shall be made whenever such Common Stock or Common Stock Equivalents
      are issued. Notwithstanding the foregoing, no adjustments shall be made, paid
      or
      issued under this Section 3(c) in respect of an Exempt Issuance (as defined
      below). The Company shall notify the Holder in writing, no later than the
      Trading Day following the issuance of any Common Stock or Common Stock
      Equivalents subject to this Section 3(c), indicating therein the applicable
      issuance price, or applicable reset price, exchange price, conversion price
      and
      other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes
      of clarification, whether or not the Company provides a Dilutive Issuance Notice
      pursuant to this Section 3(c), upon the occurrence of any Dilutive Issuance,
      after the date of such Dilutive Issuance the Holder is entitled to receive
      a
      number of Warrant Shares based upon the Base Share Price regardless of whether
      the Holder accurately refers to the Base Share Price in the Notice of Exercise.
      “Common Stock Equivalents” means any securities of the Company which would
      entitle the holder thereof to acquire at any time Common Stock, including,
      without limitation, any debt, preferred stock, rights, options, warrants or
      other instrument that is at any time convertible into or exercisable or
      exchangeable for, or otherwise entitles the holder thereof to receive, Common
      Stock. “Exempt Issuance” means the issuance of (a) shares of Common Stock or
      options to employees, officers or directors of the Company pursuant to any
      stock
      or option plan in effect on the date hereof or hereafter duly adopted for such
      purpose by a majority of the non-employee members of the Board of Directors
      of
      the Company or a majority of the members of a committee of non-employee
      directors established, (b) securities upon the exercise or exchange of or
      conversion of any securities issued hereunder and/or other securities
      exercisable or exchangeable for or convertible into shares of Common Stock
      issued and outstanding on the date hereof, provided that such securities have
      not been amended since the date hereof to increase the number of such securities
      or to decrease the exercise, exchange or conversion price of such securities,
      (c) securities issued pursuant to acquisitions or strategic transactions
      approved by a majority of the disinterested directors of the Company, but not
      securities issued in a transaction in which the Company is issuing securities
      primarily for the purpose of raising capital or to an entity whose primary
      business is investing in securities and (d) less than 50,000 shares of Common
      Stock (subject to appropriate adjustment in the event of stock splits, stock
      combinations, and the like), in the aggregate, which do not otherwise meet
      the
      conditions of clauses (a), (b) or (c) of this definition. 

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    (d)
      No
      adjustment in the Per Share Warrant Price shall be required unless such
      adjustment would require an increase or decrease of at least $0.01 per share
      of
      Common Stock; provided,
      however,
      that
      any adjustments which by reason of this subsection 3(d) are not required to
      be
      made shall be carried forward and taken into account in any subsequent
      adjustment; provided,
      further,
      however, that adjustments shall be required and made in accordance with the
      provisions of this Section 3 (other than this subsection 3(d)) not later than
      such time as may be required in order to preserve the tax-free nature of a
      distribution, if any, to the Holder of this Warrant or Common Stock issuable
      upon the exercise hereof. All calculations under this Section 3 shall be made
      to
      the nearest cent or to the nearest 1/100th of a share, as the case may be.
      

    

    (e)
      Whenever the Per Share Warrant Price or the number of Warrant Shares is adjusted
      as provided in this Section 3 and upon any modification of the rights of a
      Holder of Warrants in accordance with this Section 3, the Company shall promptly
      prepare a brief statement of the facts requiring such adjustment or modification
      and the manner of computing the same and cause copies of such certificate to
      be
      mailed to the Holders of the Warrants. The Company may, but shall not be
      obligated to unless requested the Majority of the Holders, obtain, at its
      expense, a certificate of a firm of independent public accountants of recognized
      standing selected by the Board of Directors (who may be the regular auditors
      of
      the Company) setting forth the Per Share Warrant Price and the number of Warrant
      Shares in effect after such adjustment or the effect of such modification,
      a
      brief statement of the facts requiring such adjustment or modification and
      the
      manner of computing the same and cause copies of such certificate to be mailed
      to the Holders of the Warrants.

     

    (f)
      If
      the Board of Directors of the Company shall declare any dividend or other
      distribution with respect to the Common Stock other than a cash distribution
      out
      of earned surplus, the Company shall mail notice thereof to the Holders of
      the
      Warrants not less than ten (10) days prior to the record date fixed for
      determining stockholders entitled to participate in such dividend or other
      distribution.

     

    (g)
      If,
      as a result of an adjustment made pursuant to this Section 3, the Holder of
      any
      Warrant thereafter surrendered for exercise shall become entitled to receive
      shares of two or more classes of capital stock or shares of Common Stock and
      other capital stock of the Company, the Board of Directors (whose determination
      shall be conclusive and shall be described in a written notice to the Holder
      of
      any Warrant promptly after such adjustment) shall determine, in good faith,
      the
      allocation of the adjusted Per Share Warrant Price between or among shares
      or
      such classes of capital stock or shares of Common Stock and other capital
      stock.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (h)
      Upon
      the expiration of any rights, options, warrants or conversion privileges with
      respect to the issuance of which an adjustment to the Per Share Warrant Price
      had been made, if such option, right warrant or conversion shall not have been
      exercised, the number of Warrant Shares purchasable upon exercise of this
      Warrant, to the extent this Warrant has not then been exercised, shall, upon
      such expiration, be readjusted and shall thereafter be such as they would have
      been had they been originally adjusted (or had the original adjustment not
      been
      required, as the case may be) on the basis of (A) the fact that Common Stock,
      if
      any, actually issued or sold upon the exercise of such rights, options, warrants
      or conversion privileges, and (B) the fact that such shares of Common Stock,
      if
      any, were issued or sold for the consideration actually received by the Company
      upon such exercise plus the consideration, if any, actually received by the
      Company for the issuance, sale or grant of all such rights, options, warrants
      or
      conversion privileges whether or not exercised; provided,
      however,
      that no
      such readjustment shall have the effect of decreasing the number of Warrant
      Shares purchasable upon exercise of this Warrant by an amount in excess of
      the
      amount of the adjustment initially made in respect of the issuance, sale or
      grant of such rights, options, warrants or conversion privileges.

    

    (i)
      In
      case any event shall occur as to which the other provisions of this Section
      3
      are not strictly applicable but as to which the failure to make any adjustment
      would not fairly protect the purchase rights represented by this Warrant in
      accordance with the essential intent and principles of the adjustments set
      forth
      in this Section 3 then, in each such case, the Board of Directors of the Company
      shall in good faith determine the adjustment, if any, on a basis consistent
      with
      the essential intent and principles established herein, necessary to preserve
      the purchase rights represented by the Warrants. Upon such determination, the
      Company will promptly mail a copy thereof to the Holder of this Warrant and
      shall make the adjustments described therein.

    

    4. Fully
      Paid Stock; Taxes.
      The
      shares of the Common Stock represented by each and every certificate for Warrant
      Shares delivered on the exercise of this Warrant shall, subject to compliance
      by
      the Holder with the terms hereof, at the time of such delivery, be duly
      authorized, validly issued and outstanding, fully paid and nonassessable, and
      not subject to preemptive rights or rights of first refusal imposed by any
      agreement to which the Company is a party, and the Company will take all such
      actions as may be necessary to assure that the par value, if any, per share
      of
      the Common Stock is at all times equal to or less than the then Per Share
      Warrant Price. The Company shall pay, when due and payable, any and all Federal
      and state stamp, original issue or similar taxes which may be payable in respect
      of the issue of any Warrant Share or any certificate thereof to the extent
      required because of the issuance by the Company of such security.

     

    5. Registration
      Under Act.
      

     

    (a)
      The
      Holder shall have the right to participate in the registration rights granted
      to
      the Holder pursuant to the Registration Rights Agreement of even date herewith
      between the Company and the Holder. 

     

    (b)
      Until
      all of the Warrant Shares and any shares of Common Stock issuable thereunder
      have been sold under a Registration Statement or pursuant to Rule 144, so long
      as the Company’s Common Stock remains registered under the Act, the Company
      shall use its reasonable best efforts to file with the Securities and Exchange
      Commission all current reports and the information as may be necessary to enable
      the Holder to effect sales of its shares in reliance upon Rule 144 promulgated
      under the Act.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    6. Transferability;
      Agent.
      Subject
      to compliance with any applicable securities laws, this Warrant and all rights
      hereunder are transferable, in whole or in part, upon surrender of this Warrant
      at the principal office of the Company, together with a written assignment
      of
      this Warrant substantially in the form attached hereto duly executed by the
      Holder or its agent or attorney and funds sufficient to pay any transfer taxes
      payable upon the making of such transfer. Upon such surrender and, if required,
      such payment, the Company shall execute and deliver a new Warrant or Warrants
      in
      the name of the assignee or assignees and in the denomination or denominations
      specified in such instrument of assignment, and shall issue to the assignor
      a
      new Warrant evidencing the portion of this Warrant not so assigned, and this
      Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be
      exercised by a new holder for the purchase of Warrant Shares without having
      a
      new Warrant issued. Nordic Biotech Venture Fund II K/S (“Nordic”)
      shall
      be the agent for each Holder of a Warrant issued pursuant to this Section,
      solely for purposes of receiving notices or other information required to be
      sent by the Company to the Holders or soliciting consents from the Holders.
      Each
      Holder, by accepting a Warrant, acknowledges and agrees that the Company need
      only deal with Nordic with respect to notices and consents, and that Nordic
      may
      consent to any request without consulting any such Holder. 

    

    7. Loss,
      etc., of Warrant.
      Upon
      receipt of evidence reasonably satisfactory to the Company of the loss, theft,
      destruction or mutilation of this Warrant, and of indemnity reasonably
      satisfactory to the Company, if lost, stolen or destroyed, and upon surrender
      and cancellation of this Warrant, if mutilated, the Company shall execute and
      deliver to the Holder a new Warrant of like date, tenor and
      denomination.

    

    8. Warrant
      Holder Not Stockholder.
      This
      Warrant does not confer upon the Holder any right to vote on or consent to
      or
      receive notice as a stockholder of the Company, as such, in respect of any
      matters whatsoever, nor any other rights or liabilities as a stockholder, prior
      to the exercise hereof; this Warrant does, however, require certain notices
      to
      Holders as set forth herein.

    

    9. Communication.
      No
      notice or other communication under this Warrant shall be effective or deemed
      to
      have been given unless, the same is in writing and is mailed by first-class
      mail, postage prepaid, or via recognized overnight courier with confirmed
      receipt, addressed to:

    

    (a)
      the
      Company at Manhattan Pharmaceuticals, Inc., 810 Seventh Avenue, 4th
      Floor,
      New York, New York 10019, Attn: President, or other such address as the Company
      has designated in writing to the Holder; or

    

    (b)
      the
      Holder at the address last furnished to the Company in writing by the
      Holder.

     

    10. Headings.
      The
      headings of this Warrant have been inserted as a matter of convenience and
      shall
      not affect the construction hereof.

    

    11. Applicable
      Law.
      This
      Warrant shall be governed by and construed in accordance with the law of the
      State of New York without giving effect to the principles of conflicts of law
      thereof.

    

    12. Amendment,
      Waiver, etc.
      Except
      as expressly provided herein, neither this Warrant nor any term hereof may
      be
      amended, waived, discharged or terminated other than by a written instrument
      signed by the party against whom enforcement of any such amendment, waiver,
      discharge or termination is sought; provided, however, that any provision hereof
      may be amended, waived, discharged or terminated upon the written consent of
      the
      Company and the Majority of the Holders and such amendment, waiver, discharge
      or
      termination shall be effective with respect to the Company and all
      Holders.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF,
      the
      Company has caused this Warrant to be signed by the undersigned duly authorized
      officer, this 30th day of April, 2008.

     

    
      	 	
              MANHATTAN
                PHARMACEUTICALS, INC.

            
	 	 
	 	 
	 	
              /s/
                Michael McGuinness

            
	 	
              By: Michael
                McGuinness

            
	 	
              Its:
                Chief Operating and Financial
                Officer

            

    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    SUBSCRIPTION

     

    
      	
              To:
                Manhattan Pharmaceuticals, Inc. (the “Company”) 

            	
              Dated:
                ___________

            

    

     

    The
      undersigned, pursuant to the provisions set forth in the attached Warrant (No.
      ___), hereby elects to purchase (check
      applicable box):

     

     ̈  shares
      of
      the Common Stock of Company covered by such Warrant; or 

     

     ̈  the
      maximum number of shares of Common Stock covered by such Warrant pursuant to
      the
      cashless exercise procedure set forth in subsection 1(b).

     

    The
      undersigned herewith makes payment of the full purchase price for such shares
      at
      the price per share provided for in such Warrant. Such payment takes the form
      of
(check
      applicable box or boxes):

     

     ̈  $
      _____
      in lawful money of the United States; and/or

     

     ̈  the
      cancellation of such portion of the attached Warrant as is exercisable for
      a
      total of _______ Warrant Shares (using a Fair Market Value of $ ______ per
      share
      for purposes of this calculation); and/or

     

     ̈  the
      cancellation of such number of Warrant Shares as is necessary, in accordance
      with the formula set forth in subsection 1(b), to exercise this Warrant with
      respect to the maximum number of Warrant Shares purchasable pursuant to the
      cashless exercise procedure set forth in subsection 1(b).

     

    
      	 	
              Signature: 

            	
               

            
	
               

            	 
	 	 
	 	 
	
              Address: 

            	 
	
               

            	 
	 	 
	
               

            	 

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ASSIGNMENT

    

    FOR
      VALUE
      RECEIVED _______________ (“Assignor”) hereby sells, assigns and transfers unto
      ____________________ (“Transferee”) the foregoing Warrant and all rights
      evidenced thereby, and does irrevocably constitute and appoint
      _____________________, attorney, to transfer said Warrant on the books of
      Manhattan Pharmaceuticals, Inc. By acceptance of the foregoing Warrant,
      Transferee shall become a Holder under said Warrant and subject to the rights,
      obligations and representations of Holder set forth in said
      Warrant.

    

    
      	
              ASSIGNOR:

            	
               

            	
               

            
	
               

            	
               

            	
               

            
	
              Dated:
                _______________ 

            	
              Signature:
                

            	
               

            
	
               

            	 
	 	 
	
              Address:
                

            	
               

            
	
               

            	 
	 	 

    

     

     

    
      	
              TRANSFEREE:

            	
               

            	
               

            
	
               

            	
               

            	
               

            
	
              Dated:
                _______________ 

            	
              Signature:
                

            	
               

            
	
               

            	 
	 	 
	
              Address:
                

            	
               

            
	
               

            	 
	 	 

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    PARTIAL
      ASSIGNMENT

    

    FOR
      VALUE
      RECEIVED _______________ (“Assignor”) hereby assigns and transfers unto
      ____________________ (“Transferee”) the right to purchase _______ shares of
      Common Stock, par value $0.001 per share, of Manhattan Pharmaceuticals, Inc.
      covered by the foregoing Warrant, and a proportionate part of said Warrant
      and
      the rights evidenced thereby, and does irrevocably constitute and appoint
      ____________________, attorney, to transfer such part of said Warrant on the
      books of Manhattan Pharmaceuticals, Inc. By acceptance of the proportionate
      part
      of foregoing Warrant, Transferee shall become a Holder under said proportionate
      part of said Warrant and subject to the rights, obligations and representations
      of Holder set forth in said Warrant.

     

    
      	
              ASSIGNOR:

            	
               

            	
               

            
	
               

            	
               

            	
               

            
	
              Dated:
                _______________ 

            	
              Signature:
                

            	
               

            
	
               

            	
               

            	 
	 	 	 
	
              Address:
                

            	 
	
               

            	 
	 	 

    

     

     

    
      	
              TRANSFEREE:

            	
               

            	
               

            
	
               

            	
               

            	
               

            
	
              Dated:
                _______________ 

            	
              Signature:
                

            	
               

            
	
               

            	
               

            	 
	 	 	 
	
              Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]